User menu

Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study

Bibliographic reference Furie, Richard ; Nicholls, Kathy ; Cheng, Tien-Tsai ; Houssiau, Frédéric ; Burgos-Vargas, Ruben ; et. al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. In: Arthritis & Rheumatology, Vol. 66, no. 2, p. 379-389 (2014)
Permanent URL http://hdl.handle.net/2078.1/155281
  1. Foster Mary H., T Cells and B Cells in Lupus Nephritis, 10.1016/j.semnephrol.2006.09.007
  2. 2013 http://packageinserts.bms.com/pi/pi_orencia.pdf
  3. Davis, J Rheumatol, 34, 2204 (2007)
  4. Weisman, J Rheumatol, 33, 2162 (2006)
  5. Daikh, J Immunol, 159, 3104 (1997)
  6. Daikh D. I., Wofsy D., Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide, 10.4049/jimmunol.166.5.2913
  7. Schiffer L., Sinha J., Wang X., Huang W., von Gonsdorff G., Schiffer M., Madaio M. P., Davidson A., Short Term Administration of Costimulatory Blockade and Cyclophosphamide Induces Remission of Systemic Lupus Erythematosus Nephritis in NZB/W F1 Mice by a Mechanism Downstream of Renal Immune Complex Deposition, 10.4049/jimmunol.171.1.489
  8. Mease Philip, Genovese Mark C., Gladstein Geoffrey, Kivitz Alan J., Ritchlin Christopher, Tak Paul P., Wollenhaupt Jürgen, Bahary Orna, Becker Jean-Claude, Kelly Sheila, Sigal Leonard, Teng Julie, Gladman Dafna, Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial, 10.1002/art.30176
  9. Merrill J. T., Burgos-Vargas R., Westhovens R., Chalmers A., D'Cruz D., Wallace D. J., Bae S. C., Sigal L., Becker J.-C., Kelly S., Raghupathi K., Li T., Peng Y., Kinaszczuk M., Nash P., The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial, 10.1002/art.27601
  10. Isenberg D. A., Rahman A., Allen E., Farewell V., Akil M., Bruce I. N., D'Cruz D., Griffiths B., Khamashta M., Maddison P., McHugh N., Snaith M., Teh L. S., Yee C. S., Zoma A., Gordon C., BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus, 10.1093/rheumatology/keh624
  11. Ware, SF-36 health survey: manual and interpretation guide (2000)
  12. Furie, Arthritis Rheum, 63, S962 (2011)
  13. Tan Eng M., Cohen Alan S., Fries James F., Masi Alfonse T., Mcshane Dennis J., Rothfield Naomi F., Schaller Jane Green, Talal Norman, Winchester Robert J., The 1982 revised criteria for the classification of systemic lupus erythematosus : REVISED CRITERIA FOR SLE, 10.1002/art.1780251101
  14. Weening J. J., The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited, 10.1097/01.asn.0000108969.21691.5d
  15. Churg, Renal disease: classification and atlas of glomerular disease (1982)
  16. Furie R., Nicholls K., Cheng T.T., Houssiau F., Burgos-Vargas R., Chen S.L., Hillson J., Meadows-Shropshire S., Kinaszczuk M., Merrill J.T., SAT0185 Efficacy and safety of abatacept in lupus nephritis:, 10.1136/annrheumdis-2012-eular.3132
  17. Wofsy, Arthritis Rheum, 63, S964 (2011)
  18. Wofsy D., Meadows–Shropshire S., Hillson J., Diamond B., SAT0189 Comparative analysis of alternative outcome measures for use in lupus nephritis trials, 10.1136/annrheumdis-2012-eular.3136
  19. Wofsy David, Hillson Jan L., Diamond Betty, Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions, 10.1002/art.34624
  20. Wofsy David, Hillson Jan L., Diamond Betty, Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials : Outcome Measures for Lupus Nephritis, 10.1002/art.37940
  21. , Liang Matthew H., Schur Peter H., Fortin Paul, St.Clair E. William, Balow James E., Costenbader Karen, Crofford Leslie, Pablo Paola de, Dooley Mary Anne, Finckh Axel, Gordon Caroline P., Lundberg Ingrid E., Meyrier Alain, Nived Ola, Ponticelli Claudio, Schneider Matthias K., Singh Ajay, Wallace Daniel J., The American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials, 10.1002/art.21625
  22. Gladman Dafna, Ginzler Ellen, Goldsmith Charles, Fortin Paul, Liang Matthew, Sanchez-Guerrero Jorge, Urowitz Murray, Bacon Paul, Bombardieri Stefano, Hanly John, Jones John, Hay Elaine, Symmons Deborah, Isenberg David, Kalunion Kenneth, Maddison Peter, Nived Ola, Sturfelt Gunnar, Petri Michelle, Richter Martin, Snaith Michael, Zoma Asad, The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus, 10.1002/art.1780390303
  23. Krupp Lauren B., The Fatigue Severity Scale : Application to Patients With Multiple Sclerosis and Systemic Lupus Erythematosus, 10.1001/archneur.1989.00520460115022
  24. US Food and Drug Administration 2010 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf
  25. Appel G. B., Contreras G., Dooley M. A., Ginzler E. M., Isenberg D., Jayne D., Li L.-S., Mysler E., Sanchez-Guerrero J., Solomons N., Wofsy D., , Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis, 10.1681/asn.2008101028
  26. Chan Tak Mao, Li Fu Keung, Tang Colin S.O., Wong Raymond W.S., Fang Guo Xiang, Ji Yu Lian, Lau Chak Sing, Wong Andrew K.M., Tong Matthew K.L., Chan Kwok Wah, Lai Kar Neng, Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis, 10.1056/nejm200010193431604
  27. Chan T.-M., Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis, 10.1681/asn.2004080686
  28. Ginzler Ellen M., Dooley Mary Anne, Aranow Cynthia, Kim Mimi Y., Buyon Jill, Merrill Joan T., Petri Michelle, Gilkeson Gary S., Wallace Daniel J., Weisman Michael H., Appel Gerald B., Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis, 10.1056/nejmoa043731
  29. Houssiau Frédéric A., Vasconcelos Carlos, D'Cruz David, Sebastiani Gian Domenico, Garrido Enrique de Ramon, Danieli Maria Giovanna, Abramovicz Daniel, Blockmans Daniel, Mathieu Alessandro, Direskeneli Haner, Galeazzi Mauro, Gül Ahmet, Levy Yair, Petera Peter, Popovic Rajko, Petrovic Radmila, Sinico Renato Alberto, Cattaneo Roberto, Font Josep, Depresseux Geneviève, Cosyns Jean-Pierre, Cervera Ricard, Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide : Immunosuppressive Therapy in Lupus Nephritis, 10.1002/art.10461
  30. Ginzler Ellen M, Wax Stephen, Rajeswaran Anand, Copt Samuel, Hillson Jan, Ramos Eleanor, Singer Nora G, Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial, 10.1186/ar3738
  31. Rovin Brad H., Furie Richard, Latinis Kevin, Looney R. John, Fervenza Fernando C., Sanchez-Guerrero Jorge, Maciuca Romeo, Zhang David, Garg Jay P., Brunetta Paul, Appel Gerald, , Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study, 10.1002/art.34359
  32. Mysler Eduardo F., Spindler Alberto J., Guzman Renato, Bijl Marc, Jayne David, Furie Richard A., Houssiau Frédéric A., Drappa Jorn, Close David, Maciuca Romeo, Rao Kajal, Shahdad Saba, Brunetta Paul, Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study : Ocrelizumab in Lupus Nephritis, 10.1002/art.38037
  33. Genovese Mark C., Becker Jean-Claude, Schiff Michael, Luggen Michael, Sherrer Yvonne, Kremer Joel, Birbara Charles, Box Jane, Natarajan Kannan, Nuamah Isaac, Li Tracy, Aranda Richard, Hagerty David T., Dougados Maxime, Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition, 10.1056/nejmoa050524
  34. Kremer Joel M., Genant Harry K., Moreland Larry W., Russell Anthony S., Emery Paul, Abud-Mendoza Carlos, Szechinski Jacek, Li Tracy, Ge Zhiyu, Becker Jean-Claude, Westhovens Rene, Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis : A Randomized Trial, 10.7326/0003-4819-144-12-200606200-00003
  35. Westhovens R, Robles M, Ximenes A C, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park S-H, Genant H, Peterfy C, Becker J-C, Covucci A, Helfrick R, Bathon J, Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors, 10.1136/ard.2008.101121